Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity
PARP inhibitors in prostate cancer: Case based testing and clinical decisions
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation
Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer
Novel therapies in multiple myeloma
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer
First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma
Cabozantinib in combination with atezolizumab in patients with mCRPC